TTTsutomu Tamai

Tsutomu Tamai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tsutomu Tamai has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Kohei Oda

    Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

    8 shared publications
  • Akio Ido

    Kagoshima University Graduate School of Medical and Dental Sciences

    6 shared publications
  • Haruka Sakae

    Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

    6 shared publications
  • Hirofumi Uto

    Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

    6 shared publications
  • Hiroka Onishi

    Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

    6 shared publications
  • Kaori Muromachi

    Department of Digestive and Lifestyle Disease, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890‑8520, Japan

    6 shared publications

Latest Publications

  • Reduction effect of the quantity of radiation exposure and contrast media by image support system in transarterial chemoembolization for the treatment of hepatocellular carcinoma

    by Tsutomu Tamai, Oki Taniyama, Kohei Oda, Ai Kasai, Syo Ijyuin, Haruka Sakae, Hiroka Onishi, Kazuaki Tabu, Kotaro Kumagai, Seiichi Mawatari, et al.

    We confirmed the clinical utility of a three-dimensional navigation system during transarterial chemoembolization. We evaluated 128 tumors in 91 patients enrolled between May 2015 and August 2016. We evaluated the accuracy of the three-dimensional navigation imaging system for all tumors. We compared the patients who were able to undergo route detection using three-dimensional navigation with previously treated patients who underwent transarterial chemoembolization without using three-dimensional navigation (n=21). For 38 patients who underwent super-selective microcatheter insertion after a feeding artery was identified by three-dimensional navigation, we confirmed the relationship between the tumors and contrasted liver parenchyma and divided the computed tomography hepatic arteriography findings into four grades. Grade 1: an overlap of >5 mm, Grade 2: an overlap between 0 mm and 5 mm, Grade 3: the borders of the tumor within the liver parenchyma but in contact with the edges, and Grade 4: a tumor outside the borders of the liver parenchyma. Using the three-dimensional navigation system, we identified a tumor-feeding artery in 125/128 tumors (97.6%). Furthermore, this system allowed us to significantly reduce the volume of contrast media and the radiation exposure dose in patients undergoing an evaluation. We identified 15 Grade 1 tumors (39.5%), 3 Grade 2 tumors (7.9%), 11 Grade 3 tumors (28.9%), and 9 Grade 4 tumors (23.7%) according to our definitions. The three-dimensional navigation is useful not only for patients, but also for surgeons who have relatively little experience.


  • Open Access

    Early sorafenib induction after transarterial chemoembolization for unresectable hepatocellular carcinoma: Can sorafenib after TACE improve loco‑regional control?

    by Tsutomu Tamai, Kotaro Kumagai, Haruka Sakae, Hiroka Onishi, Kazuaki Tabu, Eriko Tabu, Kaori Muromachi, Akiko Saishoji, Kohei Oda, Seiichi Mawatari, et al.

    This prospective study aimed to estimate the efficacy of sorafenib therapy after transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC). Between July 2011 and March 2013, 17 patients were enrolled, 11 of whom received sorafenib therapy. Patients who previously received TACE for HCC and whose disease progressed within a six‑month period were given 400‑800 mg sorafenib orally, once or twice daily, within the 3 weeks after a second TACE (sorafenib after TACE group). The response to treatment, time to progression (TTP), overall survival (OS), and adverse events (AEs) were recorded. Of the 113 patients who underwent initial TACE for unresectable HCC between January 1995 and January 2013, 23 patients were selected who were treated with TACE alone, and for whom the interval between the second and third TACE treatments was or 4 months prolonged TTP (5.7 months) significantly compared with use for 4 months (35.9 months) was longer than that of patients who received the drug for 4 months, TACE alone, and sorafenib for <4 months. There were three AEs of grade 3 in the present study. Two patients demonstrated a decrease in liver reserve function following sorafenib treatment, but improved immediately after sorafenib administration was stopped. Sorafenib induction early after TACE for unresectable HCC was generally well tolerated and significantly improved TTP. Further studies are required to confirm the safety and efficacy of this combination therapy.


  • Open Access

    Utility of percutaneous radiofrequency ablation alone or combined with transarterial chemoembolization for early hepatocellular carcinoma

    by Tsutomu Tamai, Akihiko Oshige, Kazuaki Tabu, Eriko Tabu, Syo Ijyuin, Haruka Sakae, Hiroka Onishi, Kaori Muromachi, Akiko Saisyoji, Kohei Oda, et al.

    Percutaneous radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) is an effective, standard therapy against small hepatocellular carcinoma (HCC). However, there is debate regarding the effectiveness of RFA combined with TACE (RFA/TACE) compared with RFA alone. These two approaches were compared for the treatment of early HCC. The present study examined 83 HCC tumors in 83 patients treated with RFA between April 2007 and August 2014 at three medical institutions. All HCCs were single hypervascular tumors, with a median diameter of 16 mm (range, 6–30 mm). The overall survival (OS) rate of all patients (n=83) was 97.5% at 1 year, 82.8% at 3 years and 48.6% at 5 years, and the local recurrence rate of all patients was 14.3% at 1 year, 32.3% at 3 years and 36.5% at 5 years. The tumor-free survival (TFS) rate of all patients was 95.1% at 1 year, 56.3% at 3 years and 23.4% at 5 years. Compared with RFA alone, RFA/TACE significantly improved OS (P10×104/µl (P=0.05) were associated with a high survival rate. Multivariate analysis identified RFA/TACE [hazard ratio (HR), 0.108; P=0.001] as an independent prognostic indicator. RFA/TACE was identified as the only independent indicator of IDR (HR: 0.467; P=0.042) and TFS (HR: 0.452; P=0.012). RFA/TACE improved OS rate, IDR and TFS compared with RFA alone. The data suggested that RFA/TACE should be considered for the treatment of single hypervascular HCC.


  • Open Access

    Malignant lymphoma with splenic rupture presenting as acute hepatic failure

    by Haruka Sakae, Tsutomu Tamai, Kohei Oda, Shinsuke Suzuki, Tsubasa Hiraki, Oki Taniyama, Sho Ijuin, Hiroka Onishi, Kazuaki Tabu, Kaori Muromachi, et al.

    症例は66歳,男性.全身倦怠感,発熱,腹痛,食思不振で近医を受診し,血小板減少,肝腎機能障害を認め,当院へ緊急入院となった.腹部超音波検査,CT検査で著明な肝脾腫と脾内占拠性病変,脾出血を認めた.急速に肝不全が進行,播種性血管内凝固症候群(disseminated intravascular coagulation:DIC)も合併し,全身状態は増悪した.第3病日には腹腔内出血を来し,第5病日に死亡した.家族の同意を得て,剖検を行った.肝腫大,著明な脾腫大を認め,脾臓は被膜の破綻,出血を伴い脾破裂をきたしていた.肝臓,脾臓には腫瘍細胞がびまん性に増殖しており,免疫染色にて悪性リンパ腫(diffuse large B-cell lymphoma:DLBCL)と診断した.今回,我々は脾破裂を伴い急性肝不全様の急激な経過を呈した悪性リンパ腫の一例を経験したので文献的考察を含めて報告する.


  • A case of primary hepatic neuroendocrine tumor in which contrast-enhanced ultrasound was useful

    by Haruka Sakae, Tsutomu Tamai, Hirofumi Uto, Kaori Muromachi, Hiroka Onishi, Jun Kadono, Michiyo Higashi, Yutaka Imoto, Masato Nagino, Akio Ido

    症例は40歳,女性.皮膚の紅斑を主訴に皮膚科を受診し,鑑別として皮膚筋炎が考えられ,悪性疾患の精査目的に施行した腹部造影CT検査にて,肝S4/8に動脈相で辺縁部から濃染し,平衡相で軽度wash outされる径32 mmの腫瘤を認めた.腹部超音波検査Bモードでは,腫瘤のほとんどは境界明瞭な高エコーを呈し,内部の一部に嚢胞状の低エコー域を認めた.腹部造影超音波検査では,腫瘍は14秒後から染影されはじめ,38秒後に全体が均一に濃染された.門脈相では均一で肝実質とほぼ等エコーであった.嚢胞状の部位は染影しなかった.後血管相のadvanced dynamic flowで明瞭なdefectを呈した.肝腫瘍生検の病理診断では,肝原発神経内分泌腫瘍(primary hepatic neuroendocrine tumor: PHNET)が考えられたため,経皮経肝的門脈塞栓術を施行後に肝右葉3区域と尾状葉切除術を施行した.肝腫瘍は免疫組織学的に,chromogranin Aとsynaptophysinが陽性で,MIB-I indexは1.4%であった.肝外に原発巣を認めなかったことから,肝原発神経内分泌腫瘍 Grade 1と診断した.PHNETは稀な疾患であり,造影超音波検査で評価した報告例は少なく,文献的考察を踏まえて報告する.


  • Two patients with pacemakers who safely underwent radiofrequency ablation with bipolar electrodes to treat primary hepatocellular carcinoma

    by Sho Ijuin, Tsutomu Tamai, Hirofumi Uto, Hiroka Onishi, Haruka Sakae, Kaori Muromachi, Akihiko Oshige, Kohei Oda, Dai Imanaka, Kotaro Kumagai, et al.

  • Horizontal transmission of de novo hepatitis B between spouses: A case report

    by Seiichi Mawatari, Hirofumi Uto, Akihiro Moriuchi, Kazuaki Tabu, Kaori Muromachi, Eriko Tabu, Kohei Oda, Dai Imanaka, Akihiko Oshige, Junichi Nakazawa, et al.

    We report a female patient with acute hepatitis B due to horizontal transmission of hepatitis B virus from her husband, who suffered from de novo hepatitis B. A 48‐year‐old man underwent peripheral blood stem cell transplantation (PBSCT) for adult T‐cell leukemia/lymphoma. Nine months after the initial treatment, he was referred to our hospital because of jaundice. Laboratory data showed elevated serum aminotransferase levels and hepatitis B surface antigen (HBsAg) positivity. We diagnosed de novo hepatitis B because a pre‐PBSCT serum sample was negative for HBsAg and positive for anti‐hepatitis B core antibody (HBcAb). His liver function improved with entecavir therapy. Two months after his diagnosis of hepatitis B, his 31‐year‐old wife was admitted with fever and appetite loss. She was diagnosed with acute hepatitis B because of increased serum aminotransferase levels and HBsAg and immunoglobulin M HBcAb positivity. Sequencing of HBV DNA in the serum obtained from both patients showed 99.9% homology. Therefore, we diagnosed her acute hepatitis B as due to horizontal transmission of de novo hepatitis B from her husband. HBV derived from de novo hepatitis B should be considered a potential source of infection, although intrafamilial transmission of de novo hepatitis B is rare.


  • Endoscopic ultrasonography-guided transmural drainage of an infected hepatic cyst due to Edwardsiella tarda: a case report

    by Hiroki Taguchi, Tsutomu Tamai, Masatsugu Numata, Hitomi Maeda, Akihiko Ohshige, Hiromichi Iwaya, Shinichi Hashimoto, Shuji Kanmura, Keita Funakawa, Hiroshi Fujita, et al.

    Infected hepatic cysts are very rare compared to simple liver cysts and abscesses. We treated a 77-year-old man with an infected hepatic cyst in the lateral segment caused by Edwardsiella tarda, which has not been previously reported as a pathogenic organism associated with infected hepatic cysts. Percutaneous drainage was temporarily effective, but infection recurred after the drainage tube was removed. We then inserted two drainage tubes into the cyst using an endoscopic ultrasonography (EUS)-guided technique, which was developed from EUS-guided fine needle aspiration (EUS-FNA). The internal drainage tube was a 7 Fr double pigtail stent, and the external tube was a 6 Fr nasobiliary drainage tube. Lavage through the external drainage tube was carried out for one week. The external drainage tube was discontinued when the patient’s condition improved significantly. Sixteen days after tube insertion, he was discharged with the internal tube draining the hepatic cyst into the stomach. Fifteen months after EUS-guided drainage, CT examination showed no recurrence of the hepatic cyst. EUS-guided drainage is an effective treatment for infected hepatic cysts.


  • Mo1840 Serum Levels of Apoptosis Inhibitor of Macrophage (AIM) are Associated With Hepatic Fibrosis and Insulin Resistance in Patients With Hepatitis C Virus-Associated Liver Disease

    by Kumiko Mera, Hirofumi Uto, Yuko Sato, Yozo Yoshimine, Kohei Oda, Dai Imanaka, Akiko Saishoji, Tsutomu Tamai, Tsuyoshi Nosaki, Akihiro Moriuchi, et al.

  • Open Access

    Hepatocyte growth factor ameliorates mucosal injuries leading to inhibition of colon cancer development in mice

    by Akio Ido, Naohisa Yamaji, Akihiro Moriuchi, Masatsugu Numata, Hitoshi Setoyama, Tsutomu Tamai, Keita Funakawa, Hiroshi Fujita, Toshio Sakiyama, Hirofumi Uto, et al.

    Hepatocyte growth factor (HGF), which facilitates the repair of injured mucosa, has the potential to be a new therapeutic agent for inflammatory bowel disease (IBD). However, given that the incidence of colorectal cancer increases continuously with disease duration in patients with IBD, the fact that HGF is a potent mitogen for intestinal epithelial cells may further heighten the risk of bowel cancer in this patient population. In this study, we examined the effects of recombinant HGF on colorectal cancer development in mice with or without experimentally induced colitis. Although HGF stimulated proliferation of colonic epithelial cells in normal mucosa, the development of colorectal cancer induced by repeated injection of azoxymethane (AOM) was significantly inhibited by HGF treatment. In a mouse model of colitis-associated cancer, colorectal cancer frequently developed despite only a single injection of AOM prior to three cycles of dextran sulfate sodium administration. However, HGF treatment significantly facilitated the repair of injured mucosa, leading to inhibition of colorectal cancer development in a dose-dependent manner. Thus, HGF-induced repair of injured mucosa inhibits rather than accelerates the development of colorectal cancer, and these results also suggest the importance of blocking the cycles of mucosal injury and repair to prevent colitis-associated colorectal cancer.